Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS Regarding CY 2020 CLFS Preliminary Payment Determinations
-
ACMG-ASHG Joint Congressional Briefing on the Undiagnosed Diseases Network
-
ACMG & ASHG Presidents’ Sign-on Letter to Congress Concerning Patent Eligibility Reform
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act
-
ACMG Comments to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act Discussion Draft
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations